Topics Covered: Overview of EGFR Small-Molecule TKIs, Update on Recent Clinical Data for Small-Molecule TKIs, Second-Line Options for the Treatment of NSCLC, Clinical Variables of Patient Benefit: Who Should We Be Treating?, EGFR Small-Molecule TKIs and Rash: What Does it Mean?, Somatic Mutations and Response to EGFR Small-Molecule TKIs, Case Studies

Conference Objectives:

Who Should Attend: This activity is designed primarily for medical oncologists and other healthcare professionals interested in the treatment of cancer.